Norihiro Nishimoto

Structure and function of a new STAT-induced STAT inhibitor

Tetsuji Naka, Masashi Narazaki, Moritoshi Hirata et al. · Nature · 1997 · 1.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Norihiro Nishimoto, Kimio Terao, Toru Mima et al. · Blood · 2008 · 810 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Lancet · 2008 · 797 citations

Medicine, Clinical Sciences, Pharmacotherapy +8

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

Norihiro Nishimoto, Kazuyuki Yoshizaki, Nobuyuki Miyasaka et al. · Arthritis & Rheumatism · 2004 · 794 citations

Life Sciences, Immunology, Pharmacotherapy +15

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Norihiro Nishimoto, Yuzuru Kanakura, Katsuyuki Aozasa et al. · Blood · 2005 · 750 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +12